ICER, in collaboration with researchers from Brown University, has published a new white paper that provides clear policy and market solutions to help manage affordable and equitable access to GLP-1 obesity medications.
The paper, entitled, “Affordable Access to GLP-1 Obesity Medications: Strategies to Guide Market Action and Policy Solutions,” seeks to present insights and lessons learned from experts, while offering a menu of options that will help all stakeholders play an active part in an innovative future of pricing, coverage, and payment for new obesity medications.
ICER will host a public webinar at 12:00pm ET on April 22, 2025 to discuss the potential market strategies and federal policy solutions outlined in the white paper. Register here for the webinar.
Date of publication: April 2025
For more information, please contact info@icer.org.
Final Documents
ICER’s President and CEO Sarah K. Emond, MPP stated:
“Obesity treatments have the potential to transform thousands of lives, but only if we ensure sustainable access for all patients. It is incumbent upon the entire health care system to focus on innovative pricing, coverage, payment, and delivery solutions, with the goal of broadening access to effective obesity medications. This paper outlines the policies and market reforms available to move beyond responding to the high costs with reduced access, while meaningfully addressing the concerns around budget impact.”
Public Comments
Closed